within Pharmacolibrary.Drugs.ATC.B;

model B01AE03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.499999999999999e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.174,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.111,
    k12             = 2.2,
    k21             = 2.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AE03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Argatroban is a synthetic direct thrombin inhibitor used primarily as an anticoagulant in the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). It is approved for clinical use and is administered intravenously, especially in situations where heparin is contraindicated.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following intravenous infusion.</p><h4>References</h4><ol><li><p>Garcia, DA, et al., &amp; Samama, MM (2012). Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> 141(2 Suppl) e24S–e43S. DOI:<a href=&quot;https://doi.org/10.1378/chest.11-2291&quot;>10.1378/chest.11-2291</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22315264/&quot;>https://pubmed.ncbi.nlm.nih.gov/22315264</a></p></li><li><p>Radulescu, VC (2017). Anticoagulation Therapy in Children. <i>Seminars in thrombosis and hemostasis</i> 43(8) 877–885. DOI:<a href=&quot;https://doi.org/10.1055/s-0036-1598004&quot;>10.1055/s-0036-1598004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28346967/&quot;>https://pubmed.ncbi.nlm.nih.gov/28346967</a></p></li><li><p>Cruz-González, I, et al., &amp; Yan, BP (2012). Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. <i>Expert opinion on drug metabolism &amp; toxicology</i> 8(11) 1483–1493. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2012.722621&quot;>10.1517/17425255.2012.722621</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22970706/&quot;>https://pubmed.ncbi.nlm.nih.gov/22970706</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AE03;
